Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
NCT03905889 · Brown University · PHASE1 · terminated · last registry update 2024-06-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding withdrawn” | – | Registry record, Brown University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CDK4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-06-24Results posted on the registry: Boehringer Ingelheim, Xentuzumab + Abemaciclib (NCT03099174)
- 2025-06-05Phase 3 first posted: Fudan University, Chemotherapy + CDK4/6 Inhibitor (NCT07005557)
- 2025-05-31Results posted on the registry: Sudipto Mukherjee, MD, PhD, MPH, Palcociclib + CPX-351 (NCT03844997)
- 2025-05-31Also stopped (terminated): Dana-Farber Cancer Institute, Ribociclib + PDR001 (NCT03294694)
- 2025-05-30Results posted on the registry: St. Joseph's Hospital and Medical Center, Phoenix, Ribociclib + Everolimus (NCT03834740)
- 2025-05-30Phase 3 first posted: Fudan University, 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy + aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor (NCT06996093)
- 2025-04-13Also stopped (terminated): Novartis Pharmaceuticals, LXH254 + LTT462 (NCT02974725)
- 2025-03-24Results posted on the registry: Fundacion Oncosur, Combination, Palbociclib + Binimetinib (NCT04494958)
- 2025-03-06Results posted on the registry: Eli Lilly and Company, Abemaciclib + Placebo (NCT03706365)
- 2025-02-27Results posted on the registry: Eli Lilly and Company, Abemaciclib + Fulvestrant (NCT05169567)
- 2025-01-07Phase 3 first posted: Pfizer, PF-07220060 + letrozole (NCT06760637)
- 2025-01-03Phase 3 first posted: Celcuity Inc, Arm A: Gedatolisib + Palbociclib + Fulvestrant + Arm B: Ribociclib + Fulvestrant (NCT06757634)
- 2024-12-13Results posted on the registry: ETOP IBCSG Partners Foundation, Paclitaxel + Trastuzumab (NCT03644186)
- 2024-12-10Results posted on the registry: National Cancer Institute (NCI), Palbociclib (NCT06390839)
- 2024-10-09Results posted on the registry: Hoffmann-La Roche, Inavolisib + Placebo (NCT04191499)
- 2024-09-19Phase 3 first posted: Danish Breast Cancer Cooperative Group, Trastuzumab deruxtecan (T-DXd) + Ribociclib with ET (NCT06585969)
- 2024-09-19Results posted on the registry: Stanford University, Abemaciclib (NCT04552769)
- 2024-08-16Results posted on the registry: Children's Oncology Group, Palbociclib + Cytarabine (NCT03792256)
- 2024-08-14Results posted on the registry: Jazz Pharmaceuticals, ZW25 (Zanidatamab) + Palbociclib (NCT04224272)
- 2024-08-07Results posted on the registry: UNC Lineberger Comprehensive Cancer Center, Cetuximab + Palbociclib (NCT03446157)
- 2024-07-30Results posted on the registry: National Cancer Institute (NCI), Abemaciclib + Copanlisib Hydrochloride (NCT03939897)
- 2024-07-29Results posted on the registry: Oana Danciu, MD, Palbociclib + Tamoxifen (NCT02668666)
- 2024-04-24Phase 3 first posted: AstraZeneca, Saruparib (AZD5305) + Camizestrant (NCT06380751)
- 2024-04-24Results posted on the registry: National Cancer Institute (NCI), Palbociclib (NCT03526250)
- 2024-04-22Phase 3 first posted: American Society of Clinical Oncology, Palbociclib 125mg + Ribociclib 600mg (NCT06377852)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision